|
• aged 6–18 years
|
|
• history of allergic rhinitis for at least 1 year
|
|
• IgE antibodies ≥0.7 kU/l to house dust mite
|
|
• no use of nasal steroids in the month before start of baseline measurements
|
|
• rhinitis symptom score of at least 4 out of 12 during last 3 months
|
|
• signed informed consent
|
|
Exclusion criteria
|
|
• severe asthma (requiring 800 mcg budesonide daily or equivalent for other inhaled steroids; or requiring >3 courses of oral prednisone/prednisolone in previous year or required hospital stay for asthma in previous year)
|
|
• sensitization to pets present at home (IgE antibodies ≥0.7 kU/l)
|
|
• planned surgery of nasal cavity
|
|
• having received immunotherapy in past 3 years
|
|
• language barrier
|
|
• contraindications to sublingual immunotherapy (as supplied by the manufacturer)
|
